| NEW YORK, Feb. 2, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO. (Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) Dear Shareholder, 2011 was an exceptionally fruitful year for Inte...continued ILNS Healthcare Drugs memory |
Thursday, February 2, 2012
Intellect Neurosciences Issues Letter to Shareholders
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment